InMed Pharmaceuticals (INM) Projected to Post Earnings on Wednesday

InMed Pharmaceuticals (NASDAQ:INM) will likely be releasing its Q4 2026 results after the market closes on Wednesday, September 23rd. Analysts expect InMed Pharmaceuticals to post earnings of ($94.4436) per share and revenue of $2.0578 billion for the quarter. Individuals can check the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Wednesday, September 9, 2026 at 7:00 AM ET.

InMed Pharmaceuticals (NASDAQ:INM) last posted its quarterly earnings results on Wednesday, September 9th. The company reported ($1.43) EPS for the quarter.

InMed Pharmaceuticals Trading Up 1.5%

Shares of INM opened at $1.38 on Tuesday. InMed Pharmaceuticals has a 52 week low of $0.57 and a 52 week high of $2.50. The firm has a market cap of $4.57 million, a price-to-earnings ratio of -0.84 and a beta of 0.98. The stock has a 50 day moving average of $1.46 and a 200-day moving average of $1.23.

Insider Activity

In related news, major shareholder Adar1 Capital Management, Llc bought 54,256 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were bought at an average cost of $1.30 per share, with a total value of $70,532.80. Following the completion of the transaction, the insider directly owned 883,761 shares of the company’s stock, valued at approximately $1,148,889.30. This trade represents a 6.54% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders acquired a total of 97,652 shares of company stock valued at $128,211 over the last quarter. 0.85% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Separately, Weiss Ratings cut InMed Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 9th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

InMed Pharmaceuticals Company Profile

InMed Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery and development of pharmaceutical products based on rare cannabinoids. The company combines cannabinoid science with drug-development expertise to investigate potential treatments for diseases with significant unmet medical needs.

Its research pipeline has included INM-901, an investigational rare-cannabinoid therapy being developed for Alzheimer’s disease, as well as earlier programs targeting conditions such as epidermolysis bullosa and glaucoma.